1,the first antibody being immobilized on a solid support;

(b) contacting the solid support with a labelled second antibody which binds selectively to multimeric vitronectin ; and

(c) determining the second antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

8. (Amended) The method of claim I wherein step (ii) comprises the steps of:

(a) simultaneously contacting the sample with a first antibody which binds selectively to multimeric vitronectin, the first antibody being immobilized on a solid support, and with a labelled second antibody which binds selectively to PAI-1 ; and

(b) determining the second antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

9. (Amended) The method of claim 1 wherein step (ii) comprises the steps of:

(a) contacting the sample with a first antibody which binds selectively to multimeric vitronectin, the first antibody being immobilized on a solid support;

(b) contacting the solid support with a labelled second antibody which binds selectively to PAI-1; and

(c) determining the second antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

10. (Amended) The method of claim 1 wherein step (ii) comprises the steps of:

(a) contacting the sample with a first antibody which binds selectively to PAI-1, the first antibody being immobilized on a solid support;

(b) contacting the solid support with a second antibody which binds selectively to multimeric vitronectin;

(c) contacting the solid support with a labelled third antibody which binds selectively to the second antibody; and

(d) determining the third antibody bound to the solid support to measure the amount of PAI-1/multimeric vitronectin complex in the sample.

11. (Amended) The method of claim 1 wherein step (ii) comprises the steps of:

(a) contacting the sample with a first antibody which binds selectively to multimeric vitronectin, the first antibody being immobilized on a solid support;

(b) contacting the solid support with a second antibody which binds s selectively to PAI-1;

(c) contacting the solid support with a labelled third antibody which binds selectively to the second antibody; and

(d) determining the third antibody bound to the solid support to measure the amount of PAI-l/multimeric vitronectin complex in the sample.

12. (Amended) The method of claim 1 wherein step (ii) comprises the steps of:

(a) contacting the sample, either simultaneously or stepwise, with a first antibody which binds selectively to PAI-1 and to which is attached one member of a capture pair and with a labelled second antibody which binds selectively to multimeric vitronectin to form a mixture;

(b) contacting the mixture with a solid support on which is immobilized the other member of the capture pair; and

(c) determining the second antibody bound to the solid support to measure the amount of PAI-l/multimeric vitronectin complex in the sample.

13. (Amended) The method of claim 1 wherein step (ii) comprises the steps of:

(a) contacting the sample either simultaneously or stepwise, with a first antibody which binds selectively to multimeric vitronectin and to which is attached one member of a capture pair and with a labelled second antibody which binds selectively to PAI-1 to form a mixture;

(b) contacting the mixture with a solid support on which is immobilized the other member of the capture pair; and

(c) determining the second antibody bound to the solid support to measure the amount of-PAI-1/multimeric vitronectin complex in the sample.

14. (Amended) The method according to claim 1 wherein the biological fluid is selected from the group consisting of whole blood, plasma, serum, urine, saliva, amniotic fluid, cerebrospinal fluid and a tissue extract.

15. (Amended) The method according to claim 1 wherein the biological fluid is whole blood, plasma or serum.

16. (Amended) The method according to claim 1 wherein the second antibody is labelled with a directly detectable label.

17. (Amended) The method according to claim 1 wherein the second antibody is labelled with a component of a signal-generating system.

19. (Amended) The method according to claim 1 wherein the second antibody is labelled with a fluorophore.

27. (Amended) The kit of claim 25 wherein said first antibody is immobilized on a solid support.

28. (Amended) The kit of claim 25 further comprising a set of calibration standards.

30. (Amended) The kit of claim 29 wherein said first antibody is immobilized on a solid support.

31. (Amended) The kit of claim 29 further comprising a set of calibration is standards.